Gossamer Bio GAAP EPS of -$7.36 misses by $2.54, revenue of $38.43M beats by $26.27M

What happened: Gossamer Bio (GOSS) reported Q3 GAAP EPS of -$7.36, which missed estimates by $2.54, while revenue of $38.43M beat estimates by $26.27M. Key numbers: GAAP EPS -$7.36, missed by $2.54. Revenue $38.43M, up 189.2% Y/Y, beat by $26.27M. Cash, cash equivalents and marketable securities $51.2 million as of September 30, 2026, versus $57.0 million as of June 30, 2026. Why it matters: Revenue beat estimates by a wide margin and grew sharply year over year, but the EPS miss came alongside a decline in cash and marketable securities, and shares fell 10% in after-hours trading. Coverage: 4 outlets in 24h

Gossamer Bio (GOSS) reported Q3 GAAP EPS of -$7.36, which missed estimates by $2.54, while revenue of $38.43M beat estimates by $26.27M.

Revenue beat estimates by a wide margin and grew sharply year over year, but the EPS miss came alongside a decline in cash and marketable securities, and shares fell 10% in after-hours trading.